Logo
TAAT e-catalog for Development partners
https://e-catalogs.taat-africa.org/org/technologies/universal-vaccination-against-newcastle-diseases
Request information View pitch brochure

Universal Vaccination against Newcastle Diseases

Low-cost vaccination for poultry

The "Universal Vaccination against Newcastle Diseases" is a comprehensive framework and methodology designed to ensure widespread and effective vaccination against the Newcastle disease in poultry. It encompasses a range of components such as thermostable vaccines like the ND I-2, logistical strategies for transportation, simplified application methods, and extensive training for vaccinators. This technology is structured to provide a systematic and accessible approach to safeguard poultry from the Newcastle disease, particularly in challenging environments and remote areas.

2

This technology is TAAT1 validated.

7•7

Scaling readiness: idea maturity 7/9; level of use 7/9

Positive or neutral impact

Adults 18 and over
Positive high
The poor
Positive medium
Women
Positive high

Positive or neutral impact

Climate adaptability
It adapts really well
Adaptability for farmers
It helps a lot
Biodiversity
It doesn't hurt them
Carbon footprint
It doesn't reduce emissions at all
Environment
It makes a big difference
Water usage
It uses the same amount of water

Problem

  • High Mortality Rates: Newcastle disease is highly contagious and can cause mortality rates as high as 100% in poultry, particularly in young chicks.
  • Limited Vaccine Uptake: Despite the availability of vaccines, there are socio-economic and structural barriers that limit their uptake by smallholder farmers.
  • Vaccine Accessibility: The distance from the nearest vaccine vendor can reduce the likelihood of farmers vaccinating their chickens.
  • Vaccine Knowledge: Lack of knowledge about the Newcastle disease and its vaccine can hinder vaccination efforts.
  • Inconsistent Vaccination: If the vaccination does not reach all the birds at the same time, some birds will have contact with the vaccine virus later on, causing a reaction.
  • Poor Vaccination Systems: Inadequate vaccination systems can lead to increased losses.

Solution

  • Thermostable Vaccines: The ND I-2 vaccine, developed from a temperature-tolerant strain of the virus, can withstand varying temperatures, making it more resilient and effective in diverse environments.
  • Improved Accessibility & Knowledge: The technology includes logistical strategies for transportation to improve accessibility. It also provides extensive training for vaccinators, enhancing their knowledge about the disease and its vaccine.
  • Efficient Vaccination Systems: The technology promotes simplified application methods and consistent vaccination, reducing the chances of disease spread and improving overall poultry health. It also addresses system inadequacies by providing a comprehensive and systematic approach to vaccination.

Key points to design your ORG TEXT

ORG specific text

In the meantime, use the “Request information” button if you need to contact us.

More

0.02 USD

A dose of the ND I-2 vaccine, is inexpensive to administer

2.5 USD

per round of vaccination for 20 chickens

250 USD

local vaccination campaign at the village level

IP

Open source / open access

Countries with a green colour
Tested & adopted
Countries with a bright green colour
Adopted
Countries with a yellow colour
Tested
Egypt Equatorial Guinea Ethiopia Algeria Angola Benin Botswana Burundi Burkina Faso Democratic Republic of the Congo Djibouti Côte d’Ivoire Eritrea Gabon Gambia Ghana Guinea Guinea-Bissau Cameroon Kenya Libya Liberia Madagascar Mali Malawi Morocco Mauritania Mozambique Namibia Niger Nigeria Republic of the Congo Rwanda Zambia Senegal Sierra Leone Zimbabwe Somalia South Sudan Sudan South Africa Eswatini Tanzania Togo Tunisia Chad Uganda Western Sahara Central African Republic Lesotho
Countries where the technology has been tested and adopted
Country Tested Adopted
Benin Tested Adopted
Botswana Tested Adopted
Burundi Tested Adopted
Central African Republic Tested Adopted
Côte d’Ivoire Tested Adopted
Democratic Republic of the Congo Tested Adopted
Ethiopia Tested Adopted
Gabon Tested Adopted
Ghana Tested Adopted
Guinea Tested Adopted
Kenya Tested Adopted
Madagascar Tested Adopted
Malawi Tested Adopted
Mozambique Tested Adopted
Nigeria Tested Adopted

This technology can be used in the colored agro-ecological zones. Any zones shown in white are not suitable for this technology.

Agro-ecological zones where this technology can be used
AEZ Subtropic - warm Subtropic - cool Tropic - warm Tropic - cool
Arid
Semiarid
Subhumid
Humid

Source: HarvestChoice/IFPRI 2009

The United Nations Sustainable Development Goals that are applicable to this technology.

Sustainable Development Goal 8: decent work and economic growth
Goal 8: decent work and economic growth

Here are the process that ensures the production, preparation, and systematic vaccination against Newcastle Disease in poultry

  1. Vaccine Production: Vaccines are produced in Africa using the "master seed egg amplification" technique from disease-free flocks. Companies like Brentec Ltd. in Uganda and DBellium Nigeria Ltd. in Jos have achieved significant production levels, with over five million and two million doses of ND I-2 vaccine respectively, supported by organizations like GALVmed in Kenya and Tanzania.
  2. Vaccination Preparation: Prior to vaccination, vaccinators conduct assessments to determine the number of households and chickens in the area. Interested households are registered, and mutually agreed-upon dates for vaccination are set.
  3. Vaccination Logistics: Vaccines are stored at 8°C until deployment to maintain their efficacy. Poultry farmers are instructed to gather their chickens in advance to ensure a smooth and organized vaccination process.
  4. Deployment and Vaccination: On the agreed-upon date, vaccinators deploy the vaccines, ensuring that all registered households and their chickens are vaccinated as planned.
  5. Post-Vaccination Procedures: Follow-up actions might include monitoring the vaccinated chickens for any adverse reactions and providing guidance or support as needed.

Last updated on 22 May 2024